Dr. Thanaporn's primary interests are in repurposing old drugs for new indications and the use of novel therapeutics in heart failure. He is also interested in heart failure outcomes and clinical trial design. He is currently co-PI for EMERALD-HF, a precision medicine heart failure trial in China using spironolactone in patients with aldehyde dehydrogenase type 2 deficiency, a common hereditary disorder that interferes with the metabolism of alcohol.
- M.D., University of Michigan
- B.S.E., Bioengineering, University of Pennsylvania
- B.A., Biology, University of Pennsylvania
Health Services Research and Policy Focus
Condition Focus
Population Focus
Affiliated Centers and Programs
U-M Academic Affiliation(s)
U-M Primary Appointment
Assistant Professor
Medical School
»
Internal Medicine
»
Hospital Medicine
Contact Information
Email
[email protected]Publications, Grants, and Research Network
Michigan Experts Profile